SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Pharmos (PARS)
An SI Board Since October 1998
Posts SubjectMarks Bans Symbol
1386 42 0 PARS
Emcee:  Dr. John M. de Castro Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1336gfp - <i>The CT info was from the 10-14-04 Bio Emerging Co Forum ConferencClarksterh-12/2/2004
1335Clark, The CT info was from the 10-14-04 Bio Emerging Co Forum Conference. Thegfp927z-12/2/2004
1334<i>If the Phase 3 results are equally compelling (of course that's alwClarksterh-12/2/2004
1333Looking at the Phase 2 results, they saw good neurological recovery (measured bygfp927z-12/2/2004
1332Fred - The european and US arms had the same criteria - both part of the same PhTony van Werkhooven-12/2/2004
1331Clark: Jan 10, 2001 pr, "Inclusion criteria *** include scoring 2-5 on thefred hayes-12/1/2004
1330<i>One possibility, but it seems non-credible, is that as you know mGCS isClarksterh-12/1/2004
1329Thanks - I think I've answered most of the obvious questions about the citicClarksterh-12/1/2004
1328citicoline/Clarksterh I noticed that you posted on the YBoard a question re: thmarin-12/1/2004
1327<i> In the published Phase 2 results, they also break down neurological reClarksterh-11/30/2004
1326Tony, Thanks, but I couldn't get the link to work. Yes, I'd be interesgfp927z-11/28/2004
1325gfp - Please take the time to review that following document - in particular theTony van Werkhooven-11/28/2004
1324<i> In the TBI Phase 2, during the initial 3 months, Dex provided a much mClarksterh-11/28/2004
1323A couple more TBI questions - 1) In the TBI Phase 2, during the initial 3 montgfp927z-11/28/2004
1322I think it is the result of reevaluation of the news release about the deaxanabiNikole Wollerstein-11/27/2004
1321Seems that the article generated INTEREST and buying pressure, and probably somemidastouch017-11/27/2004
1320I thought that resistance at $4 is Rock solid and without FDA approval would notNikole Wollerstein-11/27/2004
1319A full page article in the Globes today; Hereby the inofficial translation; Smidastouch017-11/26/2004
1318A full page article in the Globes today; Hereby the inofficial translation; Smidastouch017-11/26/2004
1317GFP - There were three distinct cohorts in the Phase II study. I don't recTony van Werkhooven-11/25/2004
1316<i>For the Phase 2 TBI study, did Pharmos release the actual data / detailClarksterh-11/25/2004
1315A couple questions for the SI board - For the Phase 2 TBI study, did Pharmos rgfp927z-11/25/2004
1314From the globs Pharmos (Nasdaq:PARS) calmed down yesterday, after Monday's srjk01-11/24/2004
1313<i>in fact I am not aware of any drug producing a positive neuroprotectantBiomaven-11/23/2004
1312Pharmos CEO: Dexanabinol can help memory problems after heart surgery 22.11.2rjk01-11/22/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News